Eli Lilly (LLY)
LLYPrice: $1023.22
Fair Value: 🔒
🔒score
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, a... more
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Ba... more
Description
Shares
| Market Cap | $965.26B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | David A. Ricks |
| IPO Date | 1972-06-01 | CAGR | 0.08% |
| Employees | 47,000 | Website | www.lilly.com |
| Div. Yield | 0.63% | Payout Ratio | 0.25% |
| Buy Back Yield | 0.54% | Total Yield | 1.17% |
LLY chart loading...
Fundamentals
Technicals
| Enterprise Value | $995.64B | P/E Ratio | 44.57 |
| Forward P/E | 21.85 | PEG Ratio | 0.78 |
| P/S Ratio | 13.1 | P/B Ratio | 35.9 |
| P/CF Ratio | 53.19 | P/FCF Ratio | 94.58 |
| EPS | $22.96 | EPS Growth 1Y | 95.99% |
| EPS Growth 3Y | 242.54% | EPS Growth 5Y | 254.71% |
| Revenue Growth 1Y | 44.7% | Gross Margin | 0.84% |
| Operating Margin | 0.46% | Profit Margin | 0.32% |
| ROE | 1.15% | ROA | 0.18% |
| ROCE | 0.4% | Current Ratio | 1.55 |
| Quick Ratio | 1.24 | Cash Ratio | 0.24 |
| Debt/Equity | 1.79 | Interest Coverage | 37.34 |
| Altman Z Score | 8.2 | Piotroski Score | 5 |